Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): Safety, efficacy, and complications

Giovanna Masci, Massimo Magagnoli, Vittorio Pedicini, Dario Poretti, Luca Castagna, Carlo Carnaghi, Emanuela Morenghi, Antonietta Del Vecchio, Rita Finotto, Giorgio Brambilla, Armando Santoro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Totally implantable or partially cuffed central venous catheters (CVC) are commonly used in cancer patients, but they are often expensive and may produce complications. To minimize costs, we have been using a low-cost, partially tunneled, silicone elastomer catheter with no Dacron cuff or antireflux valve (Vygon) since 2001. This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy. Materials and methods: A total of 458 Vygon catheters (Nutricath, Vygon) were percutaneously inserted by an interventional radiologist in 302 cancer patients. The median duration of catheter use was 93 days, mean 164.3 days (range 1-789). Main patient characteristics were as follows: number of male/female patients, 166/136; median age, 51 years; hematological/ nonhematological patients, 189/113. Results: Early complications were pneumothorax in six and hematoma in twelve of 458 implants, respectively. Thirteen out of 302 patients developed a catheter-related thrombosis. One hundred and thirty-five of 458 Vygon catheters required removal because of catheter-related complications: 68 accidental losses, 37 cases of febrile neutropenia suspected to be catheter-related, ten catheter dislodgements, ten catheter malfunctions, four local infections, three thromboses, two catheter ruptures, and one allergic reaction. Conclusion: Vygon catheters do not seem to induce more early and late complications as compared with other more expensive devices, except for disadvantage of the high incidence rate of accidental losses.

Original languageEnglish
Pages (from-to)1141-1146
Number of pages6
JournalSupportive Care in Cancer
Volume14
Issue number11
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Central Venous Catheters
Patient Safety
Catheters
Neoplasms
Thrombosis
Costs and Cost Analysis
Silicone Elastomers
Febrile Neutropenia
Polyethylene Terephthalates
Pneumothorax
Hematoma
Rupture
Hypersensitivity

Keywords

  • Cancer
  • Catheter-related complication
  • Infections
  • Thrombosis

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon) : Safety, efficacy, and complications. / Masci, Giovanna; Magagnoli, Massimo; Pedicini, Vittorio; Poretti, Dario; Castagna, Luca; Carnaghi, Carlo; Morenghi, Emanuela; Del Vecchio, Antonietta; Finotto, Rita; Brambilla, Giorgio; Santoro, Armando.

In: Supportive Care in Cancer, Vol. 14, No. 11, 11.2006, p. 1141-1146.

Research output: Contribution to journalArticle

@article{e107391aa87442ad9e37acfd16324396,
title = "Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): Safety, efficacy, and complications",
abstract = "Background: Totally implantable or partially cuffed central venous catheters (CVC) are commonly used in cancer patients, but they are often expensive and may produce complications. To minimize costs, we have been using a low-cost, partially tunneled, silicone elastomer catheter with no Dacron cuff or antireflux valve (Vygon) since 2001. This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy. Materials and methods: A total of 458 Vygon catheters (Nutricath, Vygon) were percutaneously inserted by an interventional radiologist in 302 cancer patients. The median duration of catheter use was 93 days, mean 164.3 days (range 1-789). Main patient characteristics were as follows: number of male/female patients, 166/136; median age, 51 years; hematological/ nonhematological patients, 189/113. Results: Early complications were pneumothorax in six and hematoma in twelve of 458 implants, respectively. Thirteen out of 302 patients developed a catheter-related thrombosis. One hundred and thirty-five of 458 Vygon catheters required removal because of catheter-related complications: 68 accidental losses, 37 cases of febrile neutropenia suspected to be catheter-related, ten catheter dislodgements, ten catheter malfunctions, four local infections, three thromboses, two catheter ruptures, and one allergic reaction. Conclusion: Vygon catheters do not seem to induce more early and late complications as compared with other more expensive devices, except for disadvantage of the high incidence rate of accidental losses.",
keywords = "Cancer, Catheter-related complication, Infections, Thrombosis",
author = "Giovanna Masci and Massimo Magagnoli and Vittorio Pedicini and Dario Poretti and Luca Castagna and Carlo Carnaghi and Emanuela Morenghi and {Del Vecchio}, Antonietta and Rita Finotto and Giorgio Brambilla and Armando Santoro",
year = "2006",
month = "11",
doi = "10.1007/s00520-006-0065-2",
language = "English",
volume = "14",
pages = "1141--1146",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon)

T2 - Safety, efficacy, and complications

AU - Masci, Giovanna

AU - Magagnoli, Massimo

AU - Pedicini, Vittorio

AU - Poretti, Dario

AU - Castagna, Luca

AU - Carnaghi, Carlo

AU - Morenghi, Emanuela

AU - Del Vecchio, Antonietta

AU - Finotto, Rita

AU - Brambilla, Giorgio

AU - Santoro, Armando

PY - 2006/11

Y1 - 2006/11

N2 - Background: Totally implantable or partially cuffed central venous catheters (CVC) are commonly used in cancer patients, but they are often expensive and may produce complications. To minimize costs, we have been using a low-cost, partially tunneled, silicone elastomer catheter with no Dacron cuff or antireflux valve (Vygon) since 2001. This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy. Materials and methods: A total of 458 Vygon catheters (Nutricath, Vygon) were percutaneously inserted by an interventional radiologist in 302 cancer patients. The median duration of catheter use was 93 days, mean 164.3 days (range 1-789). Main patient characteristics were as follows: number of male/female patients, 166/136; median age, 51 years; hematological/ nonhematological patients, 189/113. Results: Early complications were pneumothorax in six and hematoma in twelve of 458 implants, respectively. Thirteen out of 302 patients developed a catheter-related thrombosis. One hundred and thirty-five of 458 Vygon catheters required removal because of catheter-related complications: 68 accidental losses, 37 cases of febrile neutropenia suspected to be catheter-related, ten catheter dislodgements, ten catheter malfunctions, four local infections, three thromboses, two catheter ruptures, and one allergic reaction. Conclusion: Vygon catheters do not seem to induce more early and late complications as compared with other more expensive devices, except for disadvantage of the high incidence rate of accidental losses.

AB - Background: Totally implantable or partially cuffed central venous catheters (CVC) are commonly used in cancer patients, but they are often expensive and may produce complications. To minimize costs, we have been using a low-cost, partially tunneled, silicone elastomer catheter with no Dacron cuff or antireflux valve (Vygon) since 2001. This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy. Materials and methods: A total of 458 Vygon catheters (Nutricath, Vygon) were percutaneously inserted by an interventional radiologist in 302 cancer patients. The median duration of catheter use was 93 days, mean 164.3 days (range 1-789). Main patient characteristics were as follows: number of male/female patients, 166/136; median age, 51 years; hematological/ nonhematological patients, 189/113. Results: Early complications were pneumothorax in six and hematoma in twelve of 458 implants, respectively. Thirteen out of 302 patients developed a catheter-related thrombosis. One hundred and thirty-five of 458 Vygon catheters required removal because of catheter-related complications: 68 accidental losses, 37 cases of febrile neutropenia suspected to be catheter-related, ten catheter dislodgements, ten catheter malfunctions, four local infections, three thromboses, two catheter ruptures, and one allergic reaction. Conclusion: Vygon catheters do not seem to induce more early and late complications as compared with other more expensive devices, except for disadvantage of the high incidence rate of accidental losses.

KW - Cancer

KW - Catheter-related complication

KW - Infections

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33845398919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845398919&partnerID=8YFLogxK

U2 - 10.1007/s00520-006-0065-2

DO - 10.1007/s00520-006-0065-2

M3 - Article

C2 - 16622649

AN - SCOPUS:33845398919

VL - 14

SP - 1141

EP - 1146

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -